|
Are The Benefits Of Newer Drugs Worth Their Cost? Evidence From The 1996 MEPS
Frank R. Lichtenberg
This study analyzes data on prescribed medicines from the 1996 Medical Expenditure Panel Survey (MEPS) to examine the association between the use of newer medicines and morbidity, mortality, and health spending. We find that people consuming newer drugs were significantly less likely to die by the end of the survey and were significantly less likely to experience work-loss days than were people consuming older drugs. Our most notable finding, however, is that use of newer drugs tends to lower all types of nondrug medical spending, resulting in a substantial net reduction in the total cost of treating a given condition.
       What's this?
This article has been cited by other articles:
|
|
|
|
 
D. P. Goldman, G. F. Joyce, and Y. Zheng
Prescription Drug Cost Sharing: Associations With Medication and Medical Utilization and Spending and Health
JAMA,
July 4, 2007;
298(1):
61 - 69.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Zhang and S. B. Soumerai
Do Newer Prescription Drugs Pay For Themselves? A Reassessment Of The Evidence
Health Aff.,
May 1, 2007;
26(3):
880 - 886.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Simon
Market Access For Biopharmaceuticals: New Challenges
Health Aff.,
September 1, 2006;
25(5):
1363 - 1370.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. G. Villagra and T. Ahmed
Effectiveness Of A Disease Management Program For Patients With Diabetes
Health Aff.,
July 1, 2004;
23(4):
255 - 266.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. K. Olson
Managing Delegation in the FDA: Reducing Delay in New-Drug Review
Journal of Health Politics Policy and Law,
June 1, 2004;
29(3):
397 - 430.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C.-W. Tseng, R. H. Brook, E. Keeler, and C. M. Mangione
Impact of an Annual Dollar Limit or "Cap" on Prescription Drug Benefits for Medicare Patients
JAMA,
July 9, 2003;
290(2):
222 - 227.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
